

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

RYAN PHILLIPS UTRECHT & MACKINNON

2. Address:

1133 CONNECTICUT AVE NW #300, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: RODNEY C. HOPPE

Telephone: 2027281010

E-mail (optional): rodney@rpm.com

Senate ID #: 30187-636

House ID #:

7. Client Name: Self

PFIZER, INC

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): 60,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H. 376, Medicare's Equitable Drugs for Seniors Act of 2005 H.R. 1626, Medicare Prescription Drug Improvement Act S. 239, Medicare Enhancements for Needed Drugs Act of 2005 H.R. 752/S. 873, Medicare Prescription Drug Savings and Choice Act of 2005 H.R. 563, Prescription Drug Affordability Act of 2005 H.R. 753/ S. 184, Safe IMPORT Act of 2005, provisions dealing with pharmaceuticals H.R. 5/S. 1355, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005 S. 455, Medicare Prescription Drug Price Reduction Act of 2005

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BERZOK, MATTHEW

Covered Official Position (if applicable): N/A

Name: HOPPE, RODNEY C.

Covered Official Position (if applicable): N/A

Name: MACKINNON, JEFFREY M.

Covered Official Position (if applicable): N/A

Name: NAPPI, DOUGLAS R.

Covered Official Position (if applicable): N/A

Name: OCONNOR, GEORGE

Covered Official Position (if applicable): N/A

Name: PHILLIPS, WILLIAM D.

Covered Official Position (if applicable): N/A

Name: PLANNING, MARK D.

Covered Official Position (if applicable): N/A

Name: RYAN, THOMAS

Covered Official Position (if applicable): N/A

Name: VASAPOLI, JOSEPH V.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H.R. 700/S. 334 - Pharmaceutical Market Access & Drug Safety Act of 2005 Legislation on issues pertaining to proposed Medical Prescription drug benefits Legislation on issues regarding FDA regulation of prescription drugs Congressional oversight on drug safety S. 109/H.R. 328 - Pharmaceutical Market Access Act of 2005

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BERZOK, MATTHEW

Covered Official Position (if applicable): N/A

Name: HOPPE, RODNEY C.

Covered Official Position (if applicable): N/A

Name: MACKINNON, JEFFREY M.

Covered Official Position (if applicable): N/A

Name: NAPPI, DOUGLAS R.

Covered Official Position (if applicable): N/A

Name: O'CONNOR, GEORGE

Covered Official Position (if applicable): N/A

Name: PHILLIPS, WILLIAM D.

Covered Official Position (if applicable): N/A

Name: PLANNING, MARK D.

Covered Official Position (if applicable): N/A

Name: RYAN, THOMAS

Covered Official Position (if applicable): N/A

Name: VASAPOLI, JOSEPH V.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 15, 2007

Printed Name and Title: RODNEY C. HOPPE, PARTNER -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 15, 2007

Printed Name and Title: -